Research Topics
Species | A BadrosSummaryAffiliation: University of Maryland Country: USA Publications
| Collaborators
|
Detail Information
Publications
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioningAshraf Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Transfusion 42:205-9. 2002..Blood group incompatibility does not appear to affect the overall outcome in patients undergoing myeloablative conditioning before allogeneic BMT. Data on ABO-mismatched transplantation in the nonmyeloablative setting are limited...- Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patientsAshraf Z Badros
Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
J Clin Oncol 23:4089-99. 2005..Bcl-2 regulates the mitochondrial apoptosis pathway that promotes chemotherapy resistance. Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA... - Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioningAshraf Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
J Clin Oncol 20:1295-303. 2002..We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft)... - Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factorsAshraf Badros
University of Maryland and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
J Clin Oncol 24:945-52. 2006..To describe the clinical, radiologic, and pathologic features and risk factors for osteonecrosis of the jaw (ONJ) in multiple myeloma (MM) patients... - Results of autologous stem cell transplant in multiple myeloma patients with renal failureA Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 114:822-9. 2001..MEL-140 had an acceptable toxicity and appeared equally effective as MEL-200. In the setting of renal failure, the role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation... - Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myelomaAshraf Badros
University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
Clin Lymphoma Myeloma 7:210-6. 2006..In preclinical studies, bortezomib was shown to suppress tumor growth, sensitize malignant cells to apoptosis, and reverse chemotherapy resistance... 
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myelomaAshraf Badros
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
Clin Cancer Res 15:5250-7. 2009..Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro. We sought to test the combination clinically...- Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and waitAshraf Badros
University of Maryland, Greenebaum Cancer Center, Baltimore, MD, 21201, USA
Clin Adv Hematol Oncol 3:916-7; discussion 918. 2005 - Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literatureAshraf Badros
Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
Cancer 110:1042-9. 2007..Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)... 
Natural history of osteonecrosis of the jaw in patients with multiple myelomaAshraf Badros
University of Maryland, Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201, USA
J Clin Oncol 26:5904-9. 2008..To evaluate the natural history of bisphosphonate-related osteonecrosis of the jaw (ONJ) in patients with multiple myeloma...- Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasiaAshraf Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, USA
Leuk Lymphoma 43:1267-71. 2002..The use of thalidomide should be carefully assessed in relapsed multiple myeloma patients with clinical and cytogenetic evidence of t-MDS... - Transplantation as salvage therapy for high-risk patients with myeloma in relapseC-K Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Bone Marrow Transplant 30:873-8. 2002..001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors... - Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 yearsA Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 114:600-7. 2001..In conclusion, MEL-140 is less toxic and appears equally as efficacious as MEL-200 in elderly patients. The benefits of tandem SCT in this patient population need further evaluation in a randomized trial... - Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyM Zangari
Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 98:1614-5. 2001.... - Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor aloneK R Desikan
The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 112:242-7. 2001..Patients with high tumour burden, i.e. beta(2)-microglobulin levels > 2.5 mg/l, probably benefit from chemotherapy for mobilization both in terms of cytoreduction and adequate stem cell mobilization resulting in accelerated engraftment... - Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantationC K Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
Bone Marrow Transplant 37:511-5. 2006.... - Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsM Zangari
Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Blood Coagul Fibrinolysis 13:187-92. 2002..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT... - Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphomaA P Rapoport
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
Bone Marrow Transplant 34:883-90. 2004..5 years, EFS=87%). There were no treatment-related deaths during or after the CC phase. Post-transplant CC is feasible and well tolerated. The impact of this approach on EFS should be evaluated in a larger, randomized study... - Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patientsB Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 98:492-4. 2001..Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM... - High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsA Badros
Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
Blood 97:2574-9. 2001..Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure... - Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioningChoon Kee Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
Exp Hematol 31:73-80. 2003..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)... - Clinical activity of arsenic trioxide for the treatment of multiple myelomaN C Munshi
University of Arkansas for Medical Sciences, Myeloma and Transplantation Medical Center, Little Rock, AR, USA
Leukemia 16:1835-7. 2002..The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM... - Thalidomide in the management of multiple myelomaB Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Semin Hematol 38:250-9. 2001..The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy. Newer, more potent, and less toxic derivatives of thalidomide are being evaluated... - Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestationsAthanasios B T Fassas
Myeloma and Transplantation Research Center, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 117:103-8. 2002..Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting... - Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytomaS H Lim
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Cancer 91:900-8. 2001..The authors reasoned that if there is any specific T-cell/tumor cell interaction in myeloma, it is most likely reflected in the T-cell population in the vicinity of the tumor cells... - Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cellsA P Rapoport
Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
Bone Marrow Transplant 33:53-60. 2004..Autotransplantation followed by costimulated autologous T cells is feasible for patients with chronic phase CML, who lack allogeneic donors and can be associated with molecular remissions... - Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapyA P Rapoport
Greenebaum Cancer Center and Stem Cell Transplantation Program, University of Maryland School of Medicine, Baltimore, MD, USA
Bone Marrow Transplant 29:303-12. 2002..015). In conclusion, post-transplant consolidation therapy is feasible and well-tolerated for patients autografted for aggressive NHL and HD and may be associated with improved progression-free survival particularly for patients with HD... - Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transferAaron P Rapoport
University of Maryland Greenebaum Cancer Center and Center for Vaccine Development, 22 South Greene Street Baltimore, Maryland 21201, USA
Nat Med 11:1230-7. 2005..05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses... - Tandem transplantation in multiple myelomaJavier Bolaños-Meade
Bone Marrow Transplant Program, University of Maryland, Greenebaum Cancer Center, Blood and Marrow Transplant Program, Baltimore, Maryland, USA
Oncology (Williston Park) 17:389-98; discussion 398-400, 405-7. 2003..Until the efficacy and safety of this procedure is fully established, it should be limited to high-risk patients... - Separating graft-versus-tumor from graft-versus-host reactionsA B T Fassas
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Leuk Lymphoma 43:725-33. 2002.... - Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplantsGuido Tricot
The Myeloma and Transplantation Research Center and the Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 116:211-7. 2002..or = 7 years and re-establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression > or = 7 years... - Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
Clin Cancer Res 10:8301-8. 2004..On the basis of our preclinical studies, we designed a clinical study to test our hypothesis that MMF has antimyeloma activity... - Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosisMark A Scheper
Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland Medical Center, Baltimore, MD 21201, USA
Br J Haematol 144:667-76. 2009..These findings support the potential for soft tissue injury as an initiating/potentiating event for osteonecrosis... - A novel bioassay model to determine clinically significant bisphosphonate levelsMark A Scheper
Department of Diagnostic Sciences and Pathology, University of Maryland Medical Center, 650 W Baltimore Street, 7 N, Baltimore, MD 21201, USA
Support Care Cancer 17:1553-7. 2009..The objective of this current study was to develop a novel bioassay model representative of the oral levels of BPs in patients presenting with or at risk for BON... - Scleritis complicating zoledronic acid infusionDavid Benderson
Department of Ophthalmology, University of Maryland, Baltimore, MD 21201, USA
Clin Lymphoma Myeloma 7:145-7. 2006..Physicians prescribing these drugs should be aware of this side effect, which, if not recognized and treated appropriately, is potentially devastating. We review the published data as well as the current treatment recommendations... - Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantationBenjamin Bridges
University of Maryland, Baltimore, 21201, USA
Am J Hematol 81:535-7. 2006..Our case suggests that local cidofovir therapy for viral hemorrhagic cystitis is effective and well tolerated with no observed side effects... - Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:3849-56. 2003.... - Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literatureKarl M Kasamon
Department of Hematology, Greenebaum Cancer Center, University of Maryland, Baltimore 21201, USA
Haematologica 90:ECR17. 2005..The case is discussed in the framework of the existing literature and derives clinical practice recommendations for this rare but clinically devastating entity... - Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitorsApril Deng
Department of Dermatology, University of Maryland, Baltimore 21201, USA
Arch Dermatol 142:198-202. 2006..Although anti-TNF-alpha therapy is safe and well tolerated, various adverse cutaneous reactions have been reported... - Comparison of imaging with FDG PET/CT with other imaging modalities in myelomaRichard J Breyer
Department of Radiology, University of Maryland Medical Center, 22 South Greene St, Baltimore, MD 21201, USA
Skeletal Radiol 35:632-40. 2006..CONCLUSION: FDG PET/CT scans are useful for the management and staging of myeloma. However, if PET/CT were the sole imaging study done, it would miss many additional small lytic skeletal lesions and could miss diffuse spine involvement... - Hypothyroidism in patients with multiple myeloma following treatment with thalidomideAshraf Z Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Am J Med 112:412-3. 2002 - Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascitesYoshio Inoue
University of Maryland, School of Medicine, Department of Medicine, 22 South Greene Street Baltimore, MD 21201, USA
Leuk Res 29:715-8. 2005..Involvement of serous cavities in myeloma carries a poor prognosis, and there is currently no standard effective treatment regimen... - Case 38-2004: a large tumor of the skullAshraf Z Badros
N Engl J Med 352:1610; author reply 1610. 2005